Harvard Apparatus Regenerative Technology, Inc.
corporate_fare Company Profile
Harvard Apparatus Regenerative Technology, Inc. (OTC:HRGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for HRGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-13, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for HRGN spans 8-K, 10-K.
Recent high-impact activity:
- Harvard Regenerative Reports 402% Q1 Revenue Growth, FDA Approves Phase 1 Trial
- Harvard Apparatus Secures $300K Bridge Note from CEO Amid Going Concern Warning
- CEO Provides $300K Bridge Loan to Address Going Concern Warning
- Going Concern Warning Issued Amidst Clinical Trial Delays and Short Cash Runway
- Harvard Apparatus Secures $0.7M Private Placement, Grants Investor Board Seat, and Proposes Governance Reforms
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 1,013 shares in HRGN as of the October 30, 2026 settlement, a 48.3% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 18, 2026, 54.0% of HRGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.